Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (CASE: RMDA)
Health Care · Pharmaceuticals · EG
EGP6.20
-4.47% today · +96.8% 1Y
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (CASE: RMDA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $247.72M.
Over the last twelve months the share price has gained 96.8%, trading between 3.02 and 7.39.
Tweenvest scores Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) across four factors: quality 61/100, value 23/100, growth 79/100, dividend 27/100. Its strongest factor is growth.
RMDA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $247.72M
- Revenue (TTM)
- $89.31M
- P/E
- 41.61
- EPS
- 0.15
- Dividend yield
- 0.65%
- Beta (5Y)
- 0.44
- 52-week high
- EGP7.39
- 52-week low
- EGP3.02
- Avg volume (3M)
- —
- Shares outstanding
- 2.03B
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.